You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥(600196.SH):控股子公司HLX26聯合漢斯狀和化療一線治療晚期非小細胞肺癌臨牀試驗獲批准

格隆匯5月5日丨復星醫藥(600196.SH)公佈,控股子公司上海復宏漢霖生物製藥有限公司於近日收到國家藥品監督管理局關於同意HLX26(即重組抗LAG-3人源化單克隆抗體注射液)聯合漢斯狀®(即斯魯利單抗注射液)和化療一線治療晚期非小細胞肺癌(NSCLC)開展臨牀試驗的批准。上海復宏漢霖生物技術股份有限公司及/或其控股子公司擬於條件具備後於中國境內開展該治療方案的II期臨牀試驗。

該治療方案中所涉HLX26為本集團自主研發的靶向淋巴細胞活化基因3(LAG-3)胞外結構域的創新型人源化單抗、漢斯狀®(即斯魯利單抗注射液)為本集團自主研發的創新型抗PD-1單抗。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account